REGULATED PRESS RELEASE
News
-
-
-
PRESS RELEASE
Route1 Reports Fiscal Year 2025 Results and Continued Transition Toward Recurring, Lifecycle-Based Revenue
Route1 Inc. announces fiscal 2025 financial results focused on recurring support and services revenue growth, operational improvement capabilities, ALPR deployment, and transition to embedded participant in operational performance -
PRESS RELEASE
Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025
Haier Biomedical achieves record high international business revenue accounting for 36% of total revenue in 2025, driven by global expansion and AI-powered growth, unveiling future strategic blueprint for industry leadership -
PRESS RELEASE
EQS-Adhoc: TTL Beteiligungs- und Grundbesitz-AG postpones the publication of its 2025 annual and consolidated financial statements following a delay at Branicks Group AG
TTL Beteiligungs- und Grundbesitz-AG postpones the publication of its 2025 annual and consolidated financial statements due to a delay at Branicks Group AG -
PRESS RELEASE
Successful capital increase for the Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC)
Successful capital increase completed for Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC), raising approximately CHF74million to expand property portfolio focused on light industrial sector -
PRESS RELEASE
Augmentation de capital réussie pour le Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC)
L'augmentation de capital du Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) a été un succès, avec CHF 74 millions levés. Les investisseurs bénéficieront de la diversification et du rendement dans l'immobilier commercial suisse -
PRESS RELEASE
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S.
MindMaze Therapeutics and Vibra Healthcare announce a partnership to expand the commercial footprint of precision neurotherapeutics in the U.S., targeting large provider groups -
-
